HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NTRA
Natera, Inc.
NTRA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NTRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTRA's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NTRA PE Valuation
NTRA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NTRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NTRA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NTRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.13 | +$1.16 |
| Q2 2026 | -$1.35 | +$0.56 |
| Q1 2026 | -$1.62 | -$0.15 |
| Q4 2025 | -$1.52 | +$0.01 |
| Q3 2025 | -$2.29 | -$0.54 |
| Q2 2025 | -$1.91 | +$0.53 |
| Q1 2025 | -$1.47 | +$1.64 |
| Q4 2024 | -$1.53 | +$2.25 |
NTRA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NTRA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NTRA on profitability, with a higher operating margin.
NTRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $794M | +34% |
| Q2 2026 | $752.8M | +38% |
| Q1 2026 | $696.6M | +39% |
| Q4 2025 | $665.5M | +40% |
| Q3 2025 | $592.2M | +35% |
| Q2 2025 | $546.6M | +32% |
| Q1 2025 | $501.8M | +36% |
| Q4 2024 | $476.1M | +53% |
NTRA's revenue has grown year over year every quarter since late 2020: $794M last quarter, up 34% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8.6% | +7.9 points |
| Q2 2026 | -10% | +10 points |
| Q1 2026 | -13% | +2.4 points |
| Q4 2025 | -3.4% | +10 points |
| Q3 2025 | -16% | -7.5 points |
| Q2 2025 | -20% | -9.6 points |
| Q1 2025 | -16% | +4.4 points |
| Q4 2024 | -14% | +14 points |
NTRA's operating margin was −8.6% last quarter, up 7.9 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NTRA on cash flow, with more consistent year-over-year improvement.
NTRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.3M | -86% |
| Q2 2026 | -$8.6M | -174% |
| Q1 2026 | $18M | -20% |
| Q4 2025 | $37.8M | +8.8% |
| Q3 2025 | $37M | +4.3% |
| Q2 2025 | $11.7M | +$19.4M |
| Q1 2025 | $22.6M | +239% |
| Q4 2024 | $34.8M | +$102.4M |
NTRA has burned cash in most quarters: $52M over the past year, down 51% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NTRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NTRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +788K shares |
| 1 year | +5% | +6.9M shares |
| 3 years | +25% | +28.9M shares |
| 5 years | +56% | +51.5M shares |
| Available history | +107% | +74.5M shares |
NTRA has 144M diluted shares, up 5% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NTRA Net Leverage
NTRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NTRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 43.5 | Neutral |
NTRA's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NTRA PE vs Healthcare Sector
NTRA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NTRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $383.6 | 16% below |
| 20 week MA | $336.8 | 4.1% below |
| 50 week MA | $263.7 | 22% above |
| 100 week MA | $214.8 | 50% above |
| 200 week MA | $147.1 | 120% above |
NTRA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NTRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.7 | $111.7 | +232% |
| 2021 | $111.7 | $93.8 | -16% |
| 2022 | $93.8 | $41.5 | -56% |
| 2023 | $41.5 | $62.6 | +51% |
| 2024 | $62.6 | $160.3 | +156% |
| 2025 | $160.3 | $233.7 | +46% |
| 2026 YTD | $233.7 | $322.9 | +38% |
NTRA has the edge over HIMS on returns for 2026, with the stronger performance.